Literature DB >> 8399564

Well-informed patients with end-stage renal disease prefer peritoneal dialysis to hemodialysis.

J Ahlmén1, L Carlsson, C Schönborg.   

Abstract

One hundred and one azotemic patients, from March 1988 to March 1992, expected to be in need of active treatment of uremia within the next 6 months, were invited to four information meetings concerning conservative treatment of uremia, hemodialysis, peritoneal dialysis, and transplantation. Eighty-three percent of the invited patients attended. Another 13 started active treatment of uremia after receiving individualized information. At the end of the observation period, 37 of 97 patients had chosen continuous ambulatory peritoneal dialysis (CAPD), and 23 hemodialysis. Twenty-nine had not yet decided which mode of active treatment of uremia they wanted, and 4 patients had died. Patients choosing CAPD had a mean age of 52 years, compared to 59 years for those choosing hemodialysis. Thirty-six of 37 patients who had chosen CAPD and 19 of 23 patients who had chosen hemodialysis had started treatment. The cumulative patient and technique survival at 12 months for CAPD was 92% and 66%, and for hemodialysis 70% and 70%, respectively. The patients were asked to give their views on their choice of active treatment of uremia and the information meetings once they had started treatment. Eighty-six percent of the patients did not want to change their chosen therapy, and 88% of the patients found the information provided adequate. When patients with renal insufficiency are given adequate information, the majority prefer peritoneal dialysis to hemodialysis and are very satisfied with their choice.

Entities:  

Mesh:

Year:  1993        PMID: 8399564

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  9 in total

1.  Geographic and temporal trends in peritoneal dialysis services in the United States between 1995 and 2003.

Authors:  Virginia Wang; Shoou-Yih D Lee; Uptal D Patel; Bryan J Weiner; Thomas C Ricketts; Morris Weinberger
Journal:  Am J Kidney Dis       Date:  2010-04-10       Impact factor: 8.860

2.  Payment Reform and Health Disparities: Changes in Dialysis Modality under the New Medicare Dialysis Payment System.

Authors:  Marc Turenne; Regina Baker; Jeffrey Pearson; Chad Cogan; Purna Mukhopadhyay; Elizabeth Cope
Journal:  Health Serv Res       Date:  2017-05-30       Impact factor: 3.402

3.  Medicare's New Prospective Payment System on Facility Provision of Peritoneal Dialysis.

Authors:  Virginia Wang; Cynthia J Coffman; Linda L Sanders; Shoou-Yih D Lee; Richard A Hirth; Matthew L Maciejewski
Journal:  Clin J Am Soc Nephrol       Date:  2018-11-19       Impact factor: 8.237

4.  Impacts of Geographic Distance on Peritoneal Dialysis Utilization: Refining Models of Treatment Selection.

Authors:  Virginia Wang; Matthew L Maciejewski; Cynthia J Coffman; Linda L Sanders; Shoou-Yih Daniel Lee; Richard Hirth; Joseph Messana
Journal:  Health Serv Res       Date:  2016-04-07       Impact factor: 3.402

5.  Personal abilities in patients undergoing peritoneal dialysis and hemodialysis. A pilot study using the existence scale.

Authors:  Johannes P Schwaiger; Gertrude Kopriva-Altfahrt; Wolfgang Söllner; Paul König
Journal:  Wien Klin Wochenschr       Date:  2007       Impact factor: 1.704

6.  Pre-dialysis clinic attendance improves quality of life among hemodialysis patients.

Authors:  Christine A White; Rachel M Pilkey; Miu Lam; David C Holland
Journal:  BMC Nephrol       Date:  2002-04-05       Impact factor: 2.388

7.  Dialysis modality selection among patients attending freestanding dialysis facilities.

Authors:  M Kendix
Journal:  Health Care Financ Rev       Date:  1997

Review 8.  Home Hemodialysis (HHD) Treatment as Effective yet Underutilized Treatment Modality in the United States.

Authors:  Jihane J Hajj; Krzysztof Laudanski
Journal:  Healthcare (Basel)       Date:  2017-11-28

Review 9.  Overcoming the Underutilisation of Peritoneal Dialysis.

Authors:  Jernej Pajek
Journal:  Biomed Res Int       Date:  2015-11-11       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.